Nuclidium is a clinical-stage biotechnology company specializing in the development of next-generation copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted...
VIVES is a multi-sector fund that invests in projects with a positive societal impact
Nuclidium is a clinical-stage biotechnology company specializing in the development of next-generation copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted...
Since 1957, humanity has been launching objects into space, but most were designed to be static, rigid and non-servicable, remaining in orbit for decades without the ability to move, adapt, or be...
Emolytics is a spin-off company of UCLouvain (Belgium) which is closely supported by the Louvain Technology Transfer Office. The technology originated in the University's research center in 2009 as a...
Pierre-Antoine Mariage, co-CEO Botalys:
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Chris Buyse, co-founder and Managing Partner of Fund+:
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Willem de Vos, Prof. at University of Wageningen; Patrice Cani, Prof. at UCLouvain; Jean-Christophe Malrieu, CEO A-Mansia:
"As founders and CEO of A-mansia BioTech we experienced essential support...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to